Oppenheimer Asset Management Inc. Has $5.28 Million Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)

Oppenheimer Asset Management Inc. reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 6.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,116 shares of the biotechnology company's stock after selling 1,124 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in United Therapeutics were worth $5,276,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Illumine Investment Management LLC grew its holdings in shares of United Therapeutics by 0.7% during the first quarter. Illumine Investment Management LLC now owns 8,604 shares of the biotechnology company's stock valued at $2,652,000 after buying an additional 58 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in shares of United Therapeutics by 31.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 9,179 shares of the biotechnology company's stock valued at $2,830,000 after buying an additional 2,211 shares during the last quarter. State of Alaska Department of Revenue grew its holdings in shares of United Therapeutics by 0.8% during the first quarter. State of Alaska Department of Revenue now owns 16,692 shares of the biotechnology company's stock valued at $5,145,000 after buying an additional 135 shares during the last quarter. CWA Asset Management Group LLC grew its holdings in shares of United Therapeutics by 51.6% during the first quarter. CWA Asset Management Group LLC now owns 8,224 shares of the biotechnology company's stock valued at $2,535,000 after buying an additional 2,799 shares during the last quarter. Finally, Kingswood Wealth Advisors LLC grew its holdings in shares of United Therapeutics by 16.0% during the first quarter. Kingswood Wealth Advisors LLC now owns 741 shares of the biotechnology company's stock valued at $228,000 after buying an additional 102 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on UTHR shares. JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a report on Thursday, May 1st. Wall Street Zen cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Morgan Stanley boosted their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. Bank of America cut their price target on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday, June 11th. Finally, HC Wainwright restated a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $393.08.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Raymond Dwek sold 4,000 shares of the stock in a transaction on Monday, April 7th. The stock was sold at an average price of $284.55, for a total transaction of $1,138,200.00. Following the sale, the director now owns 1,750 shares in the company, valued at $497,962.50. This represents a 69.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 77,000 shares of company stock worth $23,110,950. Insiders own 10.30% of the company's stock.

United Therapeutics Trading Up 1.2%

United Therapeutics stock opened at $289.94 on Wednesday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82. The business's 50 day simple moving average is $301.13 and its 200 day simple moving average is $326.51. The company has a market cap of $13.08 billion, a price-to-earnings ratio of 11.57, a PEG ratio of 6.27 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the prior year, the business earned $6.17 earnings per share. United Therapeutics's revenue for the quarter was up 17.2% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.